Issues complicating precision dosing for factor VIII prophylaxis

Leonard A. Valentino,Peter L. Turecek,Herbert Gritsch,Saulius Butenas,Kenneth G. Mann

Transfusion and Apheresis Science（2018）

引用 5|浏览30

暂无评分

摘要

We previously showed that personalizing prophylaxis on the basis of an individual’s pharmacokinetic (PK) response to factor VIII (FVIII) infusion reduces joint and other bleeding events in patients with hemophilia A. We theorized that the FVIII assay used, FVIII product selected, and interpatient differences impact PK assessment and the ability to precisely dose prophylaxis.

查看译文

关键词

Hemophilia,One-stage clotting assay,Chromogenic substrate assay,FVIII concentrates,Prophylaxis,Pharmacokinetic dosing

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要